ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors

ALK inhibitor crizotinib has shown potent antitumor activity in children with refractory Anaplastic Large Cell Lymphoma (ALCL) and the opportunity to include ALK inhibitors in first-line therapies is oncoming. However, recent studies suggest that crizotinib-resistance mutations may emerge in ALCL pa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Lovisa, Federica, Cozza, Giorgio, Cristiani, Andrea, Cuzzolin, Alberto, Albiero, Alessandro, Mussolin, Lara, Pillon, Marta, Moro, Stefano, Basso, Giuseppe, Rosolen, Angelo, Bonvini, Paolo
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2015
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4395299/
https://ncbi.nlm.nih.gov/pubmed/25874976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0121378
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados